PRP and Silver Nanoparticles in Wound Healing: What Studies Show So Far

The overview shows the evidence levels for which data are available and what the highest level indicates. The presence of evidence at a particular level does not automatically prove benefit: systematic reviews and meta-analyses of silver have produced mixed results.

Chronic wounds often remain stuck in a persistent inflammatory phase, and bacterial colonization is considered one of the major barriers to healing. PRP contains platelets that release growth factors such as PDGF, VEGF and TGF-β after activation. One practical limitation is that these factors are released rapidly and remain available at the site of action only for a short time¹¹.

Silver nanoparticles release silver ions and show activity against a broad range of microorganisms in laboratory studies. The research hypothesis is therefore that a matrix containing PRP and silver could prolong regenerative signalling while reducing microbial burden. Whether these effects are additive, however, depends on how the components interact. This is where the key open questions lie.

The 2016 Cochrane review included ten randomized trials with 442 participants. For chronic wounds overall, benefit remained uncertain; for diabetic foot ulcers there was a possible advantage, but this was based on only two small studies with low-quality evidence. Four of the included studies were supported by manufacturers of PRP systems¹.

More recent meta-analyses that include a larger number of studies report clearer findings for diabetic foot ulcers^2,3,26. A 2025 meta-analysis of 15 randomized trials involving 1,010 patients reported a higher rate of complete wound healing and, on average, a shorter healing time with PRP compared with conventional care²⁶. However, heterogeneity of the preparations remains a central problem: platelet concentration, leukocyte content, activation and mode of application differ considerably between studies.

The German S3 guideline on the local treatment of hard-to-heal and chronic wounds took a more cautious view of PRP based on the 2023 evidence and made no recommendation because the evidence was uncertain²⁹. This does not necessarily contradict the more recent meta-analyses: the guideline reflects an earlier evidence base and a broader spectrum of chronic wounds, whereas current meta-analyses report positive signals mainly in diabetic foot ulcers.

Silver-containing wound dressings, including products with nanocrystalline silver, have been used for years. Silver nanoparticles in wound care are therefore not a future technology. Their clinical benefit remains controversial.

A Cochrane review of 26 randomized trials involving 2,066 participants, mainly with burns, found insufficient evidence that silver-containing dressings or creams improve healing or prevent infection. For silver sulfadiazine in burns, there were indications of slower healing⁴. Another Cochrane review of contaminated and infected wounds likewise found insufficient evidence to support a recommendation⁵.

More recent meta-analyses present a more differentiated picture. An analysis of 18 randomized trials involving 1,825 participants reported a higher healing rate for diabetic foot ulcers with silver-containing dressings, whereas the effect in venous leg ulcers was not statistically significant²⁷. A further 2025 meta-analysis of 12 studies and 808 patients also reported more favorable healing outcomes in diabetic foot ulcers, with high heterogeneity for healing time²⁸. These data concern different types of silver dressings and cannot be generalized to every form of nanosilver.

The German S3 guideline from 2023 also made no recommendation for silver-containing wound dressings because of uncertain evidence. It additionally points to possible cytotoxicity, differences in silver release and the potential for resistance development²⁹. Nevertheless, a 2012 international expert consensus paper cautions against abandoning silver dressings across the board and recommends targeted, time-limited use when microbial burden is elevated⁶. There is also a biological trade-off: silver released from wound dressings was toxic to keratinocytes and fibroblasts in cell culture, precisely the cells needed for wound closure⁷.

The following studies investigate the combination directly. One frequently cited study is deliberately included because, despite how it is sometimes presented, it does not actually test the combination.

PRP is not an inert carrier fluid but a matrix containing platelets, plasma proteins and, depending on preparation, leukocytes. Silver nanoparticles interact with all three components. The letters in the diagram correspond to the explanations alongside it.

Medical device law. Under Rule 19 in Annex VIII of Regulation (EU) 2017/745, devices incorporating nanomaterial are classified as Class III where there is a high or medium potential for internal exposure, Class IIb where that potential is low, and Class IIa where it is negligible²³. For products that place free nanoparticles onto an open wound, negligible internal exposure may be difficult to justify. The specific classification depends on the intended exposure.

Medicinal products and transfusion law. The preparation and use of autologous PRP in Germany may be subject to requirements under the Medicinal Products Act and the Transfusion Act. Section 13(2b) of the German Medicinal Products Act provides, under certain conditions, an exemption from the manufacturing authorization requirement for patient-specific preparation under the direct professional responsibility of a physician; notification, documentation and other transfusion-law obligations may also apply^24,25,30. The specific legal classification depends on the preparation and application process and on the preparation used.

Intended purpose and combination. The intended purpose of a PRP system relates to the preparation process specified by the manufacturer. Adding other substances is covered by the intended system only if this is supported by the manufacturer’s information and regulatory documentation. Reliable human safety data are lacking for point-of-care combinations with nanosilver preparations not intended for that purpose; such an approach therefore cannot be inferred from preclinical studies.

For further technical and professional context on PRP, the following background articles may be useful. These links describe PRP preparation and the existing evidence; they do not constitute a recommendation to combine PRP with silver nanoparticles.

What are PRP tubes? · Matching PRP tubes and centrifuges correctly · PRP and wound healing: evidence and interpretation

Combining PRP and silver nanoparticles is an actively studied preclinical strategy, particularly as part of hydrogel wound dressings. The clinical evidence is limited to one study that does not test the actual combination effect.

Laboratory findings also show interactions that call a simple addition of effects into question: silver nanoparticles can affect platelet function, plasma proteins alter the particles, and PRP has antimicrobial activity of its own. Based on the evidence available in 2026, it is not possible to determine whether patients with chronic wounds benefit from the combination. Answering this question requires studies with complete control groups, standardized PRP preparations and clinically relevant endpoints.